GlassScriptPhysician profile
Robert A Havard
NPI 1225002694
$29,243.26
in general payments reported to CMS, 2019-2025
81 companies · $1,087 in 2025
The $1,087 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,344 · 2020: $3,100 · 2021: $4,547 · 2022: $6,332 · 2023: $7,003 · 2024: $3,831 · 2025: $1,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,698 · Long Term Medical Supply Or Device Loan: $2,196 · Education: $26.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,697.85 |
| Long Term Medical Supply Or Device Loan | $2,196.36 |
| Education | $26.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,644.41 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,097.02 | 2019-2025 | Tagrisso, Lynparza, Calquence |
| E.R. Squibb & Sons, L.L.C. | $1,926.01 | 2019-2024 | Opdivo, Opdualag |
| Exelixis INC. | $1,696.52 | 2019-2025 | Cabometyx |
| Janssen Biotech, INC. | $1,495.26 | 2019-2024 | Darzalex, Tecvayli, Imbruvica |
| Glaxosmithkline, LLC. | $1,494.59 | 2020-2024 | Ojjaara, Zejula, Jemperli |
| Amgen INC. | $1,453.88 | 2019-2023 | Lumakras, Xgeva, Vectibix |
| Eisai INC. | $1,052.28 | 2019-2024 | |
| Genentech USA, INC. | $1,039.83 | 2019-2024 | Polivy, Lunsumio, Venclexta |
| Merck Sharp & Dohme LLC | $1,009.95 | 2019-2024 | Keytruda, Lynparza |
| Celgene Corporation | $970.01 | 2019-2024 | Reblozyl, Pomalyst, Opdualag |
| Daiichi Sankyo INC. | $886.71 | 2019-2024 | Enhertu, Injectafer |
| Pfizer INC. | $724.70 | 2019-2024 | |
| Genzyme Corporation | $602.43 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $602.15 | 2019-2023 |
Show all 81 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $563.35 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $527.67 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Sobi, INC | $456.56 | 2022-2024 | |
| Incyte Corporation | $381.93 | 2019-2024 | Monjuvi, Jakafi |
| Gilead Sciences, INC. | $367.97 | 2019-2023 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $357.86 | 2019-2025 | Iclusig, Fruzaqla, Alunbrig |
| Regeneron Healthcare Solutions, INC. | $333.51 | 2019-2023 | Libtayo |
| Secura Bio, INC. | $316.68 | 2021-2023 | Copiktra |
| Alexion Pharmaceuticals, INC. | $294.09 | 2019-2023 | Ultomiris |
| Puma Biotechnology, INC. | $279.49 | 2019-2024 | |
| Astellas Pharma US INC | $278.86 | 2019-2025 | Vyloy, Xospata, Padcev |
| Morphosys, US INC. | $268.79 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $267.93 | 2021-2024 | Fotivda |
| Emd Serono, INC. | $265.73 | 2019-2024 | Bavencio |
| Ipsen Biopharmaceuticals, INC | $225.28 | 2021-2024 | Onivyde, Tazverik |
| Pharmacyclics LLC, An Abbvie Company | $193.97 | 2019-2022 | |
| Array Biopharma INC | $188.06 | 2020-2024 | Braftovi, Lorbrena, Xalkori |
| Blueprint Medicines Corporation | $168.19 | 2021-2023 | Ayvakit |
| Dova Pharmaceuticals | $163.34 | 2019-2021 | |
| Stemline Therapeutics INC. | $153.20 | 2019-2023 | Orserdu |
| Kite Pharma, INC. | $145.70 | 2021-2023 | |
| Clovis Oncology, INC. | $143.73 | 2019-2022 | |
| Karyopharm Therapeutics INC. | $140.93 | 2020-2023 | Xpovio |
| Apellis Pharmaceuticals, INC. | $139.33 | 2023-2024 | Empaveli |
| Coherus Oncology, INC. | $121.59 | 2021-2024 | |
| Abbvie INC. | $114.99 | 2021-2023 | |
| Servier Pharmaceuticals LLC | $114.11 | 2022-2024 | |
| Rigel Pharmaceuticals, INC. | $103.05 | 2022-2023 | Tavalisse, Rezlidhia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.98 | 2022-2024 | Gilotrif |
| Tesaro, INC. | $90.99 | 2019 | |
| Tersera Therapeutics LLC | $90.63 | 2019-2022 | |
| Adc Therapeutics America, INC. | $75.66 | 2022-2024 | |
| Mirati Therapeutics, INC. | $74.20 | 2023-2024 | Krazati |
| Jazz Pharmaceuticals INC. | $73.60 | 2019-2024 | |
| Octapharma USA, INC. | $72.86 | 2019 | |
| Taiho Oncology, INC. | $65.95 | 2019-2023 | |
| Accord Healthcare, INC. | $63.45 | 2024 | |
| Acrotech Biopharma INC. | $59.67 | 2021-2024 | Beleodaq |
| Pharmacosmos Therapeutics INC. | $52.80 | 2022-2023 | Monoferric |
| Beigene USA, INC. | $49.84 | 2022-2023 | Brukinsa |
| Myriad Genetic Laboratories, INC. | $43.76 | 2022 | |
| Kyowa Kirin, INC. | $40.01 | 2019-2022 | |
| G1 Therapeutics, INC. | $39.49 | 2022-2023 | Cosela |
| Medtronic, INC. | $37.27 | 2022-2024 | Osteocool Rf Ablation System |
| Deciphera Pharmaceuticals INC. | $35.05 | 2022-2024 | Qinlock |
| Mayne Pharma Commercial LLC | $33.87 | 2022 | |
| Myovant Sciences INC. | $30.12 | 2021-2022 | |
| Immunogen, INC. | $29.20 | 2024 | Elahere |
| Cti Biopharma Corp. | $27.17 | 2023 | Vonjo |
| Janssen Pharmaceuticals, INC | $25.67 | 2019-2022 | |
| Epizyme, INC. | $23.82 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $21.38 | 2024 | Triptodur |
| Fresenius Kabi USA, LLC | $18.48 | 2023 | Stimufend |
| Eusa Pharma (US) LLC | $18.26 | 2022 | |
| Recordati_rare_diseases_inc. | $18.10 | 2023 | Sylvant |
| Fennec Pharmaceuticals, INC. | $17.98 | 2024 | Pedmark |
| Heron Therapeutics, INC. | $17.39 | 2021 | |
| Dendreon Pharmaceuticals LLC | $17.27 | 2019 | |
| Spectrum Pharmaceuticals INC. | $16.55 | 2019 | |
| Sirtex Medical INC | $15.54 | 2019-2020 | |
| Acceleron Pharma, INC. | $14.93 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $13.46 | 2023 | Sancuso |
| Aurobindo Pharma USA, INC. | $13.33 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.17 | 2020 | |
| Mylan Institutional INC. | $10.90 | 2019 | |
| Agios Pharmaceuticals, INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
Kisqali $2,325Cabometyx $1,011Keytruda $439Enhertu $369Lynparza $305Lenvima $301Ojjaara $298Reblozyl $281Doptelet $272Darzalex $269Copiktra $265Polivy $259Lunsumio $254Zejula $231Tecvayli $210Tagrisso $208Pluvicto $201Lutathera $178Opdivo $167Imbruvica $160Cablivi $158Enjaymo $158Calquence $156Libtayo $154Jemperli $144Venclexta $131Imfinzi $128Verzenio $126Empaveli $125Onivyde $122Opdualag $122Bavencio $115Sarclisa $114Erleada $113Xalkori $109Lorbrena $109Mektovi $109Braftovi $109Orserdu $103Scemblix $99.87Tasigna $99.87Fotivda $99.32Promacta $98.51Stivarga $95.53Vitrakvi $95.53Tukysa $93.92Piqray $91.74Ibrance $90.13Phesgo $87.53Carvykti $83.75Udenyca $83.28Xtandi $82.18Inlyta $82.18Pomalyst $79.36Mekinist $79.22Fabhalta $78.17Retevmo $78.16Jaypirca $78.16Krazati $74.20Lumakras $73.62Gilotrif $72.64Talvey $70.88Iclusig $69.30Tecentriq $67.49Trodelvy $66.46Ultomiris $64.41Camcevi $63.45Talzenna $63.44Monjuvi $63.17Shingrix $62.70Tavalisse $59.99Rezlidhia $59.99Xpovio $57.40Jakafi $51.70Injectafer $48.94Columvi $47.10Fruzaqla $45.62Xofigo $45.55Nubeqa $45.55Bosulif $43.33Idhifa $39.70Tibsovo $39.70Zepzelca $37.46Inqovi $32.57Lonsurf $32.57Paxlovid $31.52Padcev $30.54Elahere $29.20Vyloy $27.42Vonjo $27.17Osteocool Rf Ablation System $25.43Ayvakit $23.88Monoferric $23.48Xospata $23.29Oncaspar $22.67Triptodur $21.38Alunbrig $20.93Adcetris $20.25Elrexfio $19.33Stimufend $18.48
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Havard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.